A proposed medication score for long-term trials of treatment of canine atopic dermatitis sensu lato
dc.creator | Saridomichelakis M.N., Favrot C., Jackson H.A., Bensignor E., Prost C., Mueller R.S. | en |
dc.date.accessioned | 2023-01-31T09:54:01Z | |
dc.date.available | 2023-01-31T09:54:01Z | |
dc.date.issued | 2021 | |
dc.identifier | 10.1002/vetr.19 | |
dc.identifier.issn | 00424900 | |
dc.identifier.uri | http://hdl.handle.net/11615/78796 | |
dc.description.abstract | Background: The use of concurrent medications is necessary in trials of treatment of canine atopic dermatitis. Our aim was to use the best available evidence to construct and then to validate a medication score (MS) formula that will estimate the impact of concurrent medications on trial outcomes. Methods: Trials of 15 interventions were scrutinized to find those that were consistent in terms of specific medication, administration route and dosage regimen. A MS was constructed in five steps, starting from assigning a score of 1 for each day on oral prednisone, prednisolone or methylprednisolone at 0.5–1.0 mg/kg. The MS score was validated using the clinical records of 35 dogs with atopic dermatitis that had been treated for a period of 12 ± 2 weeks with six of these medications and compared with a previously published non-validated MS. Results: A MS could be assigned to eight treatments, six of which had been administered to the 35 dogs. A positive correlation was seen with the previously published MS and a negative correlation with changes in lesional and pruritus scores. Conclusion: This MS may be a useful tool in new studies evaluating the efficacy of treatments in canine atopic dermatitis. © 2021 British Veterinary Association | en |
dc.language.iso | en | en |
dc.source | Veterinary Record | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102017050&doi=10.1002%2fvetr.19&partnerID=40&md5=6569de5bc0156ea688c4a9a22e0c3666 | |
dc.subject | alimemazine | en |
dc.subject | antifungal agent | en |
dc.subject | antiinfective agent | en |
dc.subject | barazone | en |
dc.subject | budesonide | en |
dc.subject | ceramide | en |
dc.subject | cetirizine | en |
dc.subject | chlorpheniramine maleate | en |
dc.subject | cholesterol | en |
dc.subject | cyclosporine | en |
dc.subject | dimetindene | en |
dc.subject | essential fatty acid | en |
dc.subject | fexofenadine | en |
dc.subject | genesis | en |
dc.subject | hydrocortisone aceponate | en |
dc.subject | hydroxyzine | en |
dc.subject | lokivetmab | en |
dc.subject | masitinib | en |
dc.subject | methylprednisolone | en |
dc.subject | oclacitinib | en |
dc.subject | prednisolone | en |
dc.subject | prednisone | en |
dc.subject | recombinant gamma interferon | en |
dc.subject | recombinant interferon | en |
dc.subject | recombinant omega interferon | en |
dc.subject | shampoo | en |
dc.subject | tacrolimus | en |
dc.subject | triamcinolone | en |
dc.subject | unclassified drug | en |
dc.subject | animal experiment | en |
dc.subject | Article | en |
dc.subject | atopic dermatitis | en |
dc.subject | Canis | en |
dc.subject | correlational study | en |
dc.subject | Dermatophagoides | en |
dc.subject | desensitization | en |
dc.subject | long term care | en |
dc.subject | medication score | en |
dc.subject | nonhuman | en |
dc.subject | scoring system | en |
dc.subject | supplementation | en |
dc.subject | treatment duration | en |
dc.subject | treatment outcome | en |
dc.subject | animal | en |
dc.subject | atopic dermatitis | en |
dc.subject | combination drug therapy | en |
dc.subject | dog | en |
dc.subject | dog disease | en |
dc.subject | female | en |
dc.subject | male | en |
dc.subject | treatment outcome | en |
dc.subject | veterinary medicine | en |
dc.subject | Animals | en |
dc.subject | Dermatitis, Atopic | en |
dc.subject | Dog Diseases | en |
dc.subject | Dogs | en |
dc.subject | Drug Therapy, Combination | en |
dc.subject | Female | en |
dc.subject | Male | en |
dc.subject | Treatment Outcome | en |
dc.subject | John Wiley and Sons Inc | en |
dc.title | A proposed medication score for long-term trials of treatment of canine atopic dermatitis sensu lato | en |
dc.type | journalArticle | en |
Αρχεία σε αυτό το τεκμήριο
Αρχεία | Μέγεθος | Τύπος | Προβολή |
---|---|---|---|
Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο. |